These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Targeting the Pathological Hallmarks of Alzheimer's Disease Through Nanovesicleaided Drug Delivery Approach. Roy R; Bhattacharya P; Borah A Curr Drug Metab; 2022; 23(9):693-707. PubMed ID: 35619248 [TBL] [Abstract][Full Text] [Related]
25. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics. Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764 [TBL] [Abstract][Full Text] [Related]
26. Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. Barbara R; Belletti D; Pederzoli F; Masoni M; Keller J; Ballestrazzi A; Vandelli MA; Tosi G; Grabrucker AM Int J Pharm; 2017 Jun; 526(1-2):413-424. PubMed ID: 28495580 [TBL] [Abstract][Full Text] [Related]
27. The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer's Disease: Role for Natural Antioxidants and Immunotherapeutics. Ali J; Choe K; Park JS; Park HY; Kang H; Park TJ; Kim MO Antioxidants (Basel); 2024 Jul; 13(7):. PubMed ID: 39061930 [TBL] [Abstract][Full Text] [Related]
28. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Cano A; Ettcheto M; Chang JH; Barroso E; Espina M; Kühne BA; Barenys M; Auladell C; Folch J; Souto EB; Camins A; Turowski P; García ML J Control Release; 2019 May; 301():62-75. PubMed ID: 30876953 [TBL] [Abstract][Full Text] [Related]
29. Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. Han Y; Chu X; Cui L; Fu S; Gao C; Li Y; Sun B Drug Deliv; 2020 Dec; 27(1):502-518. PubMed ID: 32228100 [TBL] [Abstract][Full Text] [Related]
30. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer's disease. Sun D; Li N; Zhang W; Zhao Z; Mou Z; Huang D; Liu J; Wang W Colloids Surf B Biointerfaces; 2016 Dec; 148():116-129. PubMed ID: 27591943 [TBL] [Abstract][Full Text] [Related]
31. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease. Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603 [TBL] [Abstract][Full Text] [Related]
32. Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer's Disease. Ma TJ; Gao J; Liu Y; Zhuang JH; Yin C; Li P; Mao L; Xu J; Xu YX; Li YP; Zhao ZX; Yin Y Mini Rev Med Chem; 2018; 18(12):1035-1046. PubMed ID: 29243575 [TBL] [Abstract][Full Text] [Related]
33. Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. Jan AT; Azam M; Rahman S; Almigeiti AMS; Choi DH; Lee EJ; Haq QMR; Choi I Front Aging Neurosci; 2017; 9():356. PubMed ID: 29163138 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]